Oral 25-Hydroxycholesterol Suppresses 4T1 Tumour Growth in an Immune-Context-Associated Manner
International Journal of Molecular Sciences · 30.10.2026 · 27 (21) · 9735
DOI: 10.3390/ijms27219735 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 30.10.2026. Verfasst von Shuo Liang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China. Hauptthemen laut MEDLINE: Hydroxycholesterols, Triple Negative Breast Neoplasms. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, World Federation of Chinese Medicine Societies, Health Commission of Jiangsu Province.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is an aggressive subtype with limited targeted-treatment options. 25-Hydroxycholesterol (25-HC) is an oxysterol involved in metabolic and immune regulation, but its antitumour effects remain context dependent. We examined whether oral 25-HC suppresses 4T1 tumour growth in immunocompetent BALB/c mice and whether host immune status modifies the response. Mice bearing 4T1 tumours received oral vehicle or 25-HC (1 or 10 mg/kg) daily for 14 days (n = 6 per group). 25-HC reduced endpoint tumour volume from 1510.6 ± 235.4 mm3 (vehicle) to 1147.2 ± 243.1 and 866.7 ± 206.6 mm3 (adjusted p = 0.027 and 0.0004); the 10 mg/kg dose also reduced tumour weight and Ki-67 positivity, increased CD8-positive T-cell infiltration and the granzyme B (GZMB)-positive fraction, reduced M2-like macrophages and raised the M1/M2 ratio. Tumour-tissue adenosine monophosphate-activated protein kinase (AMPK) signalling was altered, with p-AMPK/AMPK increased to 1.23- and 1.57-fold of control and p-STAT6/STAT6 decreased to 0.81- and 0.46-fold. Serum 25-HC increased with dose, while intratumoral 25-HC was lowest at 10 mg/kg; no dose-associated reduction was observed in BALB/c nude mice. Oral 25-HC thus suppressed 4T1 tumour growth with immune-context-associated features; however, the treatment-by-host interaction did not reach statistical significance (p = 0.06), and immune-context association of the response remains suggestive rather than established. The reciprocal serum–tumour pattern, a descriptive observation from a single time point whose cause remains unclear, generates a testable hypothesis of immune-cell-associated 25-HC handling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
- School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing 210029, China.
ORCID-Profile: Chang Yao
Förderung
- National Natural Science Foundation of China
- World Federation of Chinese Medicine Societies
- Health Commission of Jiangsu Province
- Affiliated Hospital of Nanjing University of Chinese Medicine
Zitieren
APA
Liang, S., Xu, J., Wang, Z., Liu, Y., Xu, Y., Yao, C., & Zhu, Z. (2026). Oral 25-Hydroxycholesterol Suppresses 4T1 Tumour Growth in an Immune-Context-Associated Manner. International Journal of Molecular Sciences, 27(21), 9735. https://doi.org/10.3390/ijms27219735
Vancouver
Liang S, Xu J, Wang Z, Liu Y, Xu Y, Yao C, et al. Oral 25-Hydroxycholesterol Suppresses 4T1 Tumour Growth in an Immune-Context-Associated Manner. International Journal of Molecular Sciences. 2026;27(21):9735. doi:10.3390/ijms27219735
BibTeX
@article{Liang2026,
author = {Liang, Shuo and Xu, Jingyao and Wang, Zining and Liu, Yuhao and Xu, Yanlei and Yao, Chang and Zhu, Zhiyuan},
title = {Oral 25-Hydroxycholesterol Suppresses 4T1 Tumour Growth in an Immune-Context-Associated Manner},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9735},
doi = {10.3390/ijms27219735}
}
EUVIMED